Premium
Treatment of refractory oral lichen planus using direct antiviral agents in a patient with chronic hepatitis C: A case report
Author(s) -
Harada Koji,
Nakashima Daisuke,
Nagao Yumiko,
Hidaka Isao,
Sakaida Isao,
Mishima Katsuaki
Publication year - 2020
Publication title -
oral science international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.256
H-Index - 13
eISSN - 1881-4204
pISSN - 1348-8643
DOI - 10.1002/osi2.1070
Subject(s) - medicine , sofosbuvir , oral lichen planus , ribavirin , mucocutaneous zone , hepatitis c virus , refractory (planetary science) , hepatitis c , simeprevir , chronic hepatitis , gastroenterology , dermatology , interferon , antiviral treatment , virus , immunology , disease , astrobiology , physics
Abstract Oral lichen planus (OLP) is a chronic inflammatory and immunologically mediated mucocutaneous disease with a high prevalence in hepatitis C virus (HCV)‐infected patients. Interferon (IFN)‐free direct‐acting antiviral drugs (DAA) have been recommended for the treatment of patients with extrahepatic manifestations of HCV infection. Herein, we present the case of a 65‐year‐old woman who was diagnosed with OLP and chronic hepatitis C. She received DAA treatment with sofosbuvir (SOF) and ribavirin (RBA) at 75 years of age, which led to partial disappearance of the OLP and complete eradication of HCV. Thus, the patient was effectively treated without any major side effects.